About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

TELA Bio, Inc. - Common stock (NQ:TELA)

0.6901 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about TELA Bio, Inc. - Common stock

< Previous 1 2 3 4 Next >
News headline image
TELA Bio Reports Fourth Quarter and Full Year 2025 Financial Results
From TELA Bio, Inc.
Via GlobeNewswire
News headline image
TELA Bio to Announce Fourth Quarter and Full Year 2025 Financial Results
From TELA Bio, Inc.
Via GlobeNewswire
News headline image
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From TELA Bio, Inc.
Via GlobeNewswire
News headline image
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From TELA Bio, Inc.
Via GlobeNewswire
News headline image
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From TELA Bio, Inc.
Via GlobeNewswire
News headline image
TELA Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference
From TELA Bio, Inc.
Via GlobeNewswire
News headline image
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From TELA Bio, Inc.
Via GlobeNewswire
News headline image
TELA Bio Announces Pricing of $13.0 Million Underwritten Registered Direct Offering of Common Stock and Pre-Funded Warrants
From TELA Bio, Inc.
Via GlobeNewswire
News headline image
TELA Bio Reports Third Quarter 2025 Financial Results and Refinancing and Upsizing of Credit Facility
From TELA Bio, Inc.
Via GlobeNewswire
News headline image
TELA Bio to Announce Third Quarter 2025 Financial Results
From TELA Bio, Inc.
Via GlobeNewswire
News headline image
TELA Bio Appoints William Plovanic to Board of Directors
From TELA Bio, Inc.
Via GlobeNewswire
News headline image
TELA Bio Announces Addition of Betty Jo Rocchio to Board of Directors and the Departure of Director Lisa Colleran
From TELA Bio, Inc.
Via GlobeNewswire
News headline image
TELA Bio Reports Second Quarter 2025 Financial Results
From TELA Bio, Inc.
Via GlobeNewswire
News headline image
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From TELA Bio, Inc.
Via GlobeNewswire
News headline image
TELA Bio to Participate in the Canaccord Genuity 45th Annual Growth Conference
From TELA Bio, Inc.
Via GlobeNewswire
News headline image
TELA Bio to Announce Second Quarter 2025 Financial Results
From TELA Bio, Inc.
Via GlobeNewswire
News headline image
TELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From TELA Bio, Inc.
Via GlobeNewswire
News headline image
TELA Bio Announces European Commercial Launch of OviTex® Inguinal for Robotic and Laparoscopic Inguinal Hernia Repair
Based on market research, inguinal hernia repair is the most common type of hernia repair 
From TELA Bio, Inc.
Via GlobeNewswire
News headline image
TELA Bio Appoints Jeffrey Blizard as President
Company Further Strengthens Executive Leadership Team to Drive Next Phase of Growth 
From TELA Bio, Inc.
Via GlobeNewswire
News headline image
TELA Bio to Participate in the 2025 Jefferies Global Healthcare Conference
From TELA Bio, Inc.
Via GlobeNewswire
News headline image
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From TELA Bio, Inc.
Via GlobeNewswire
News headline image
TELA Bio Reports First Quarter 2025 Financial Results
From TELA Bio, Inc.
Via GlobeNewswire
News headline image
TELA Bio to Announce First Quarter 2025 Financial Results
From TELA Bio, Inc.
Via GlobeNewswire
News headline image
TELA Bio Announces U.S. Commercial Launch of Larger Sizes of OviTex® PRS for Plastic and Reconstructive Surgery
The OviTex PRS portfolio now includes a larger option than any human acellular dermal matrix product on the market 
From TELA Bio, Inc.
Via GlobeNewswire
News headline image
TELA Bio Reports Fourth Quarter and Full Year 2024 Financial Results
From TELA Bio, Inc.
Via GlobeNewswire
News headline image
TELA Bio to Announce Fourth Quarter and Full Year 2024 Financial Results
From TELA Bio, Inc.
Via GlobeNewswire
News headline image
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From TELA Bio, Inc.
Via GlobeNewswire
News headline image
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From TELA Bio, Inc.
Via GlobeNewswire
News headline image
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From TELA Bio, Inc.
Via GlobeNewswire
News headline image
TELA Bio to Participate in Piper Sandler’s 36th Annual Healthcare Conference
From TELA Bio, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.